Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2016, Article ID 1678495, 5 pages
http://dx.doi.org/10.1155/2016/1678495
Clinical Study

The Effectiveness of Intraocular Methotrexate in the Treatment of Posterior Uveitis in Behçet’s Disease Patients Compared to Retrobulbar Steroids Injection

1Beni Suef University, Beni Suef, Egypt
2Cairo University, Giza, Egypt

Received 19 August 2016; Revised 24 October 2016; Accepted 14 November 2016

Academic Editor: Jesús Pintor

Copyright © 2016 Hossam El Din Mohamed Khalil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Sakane, M. Takeno, N. Suzuki, and G. Inaba, “Behcet's disease,” New England Journal of Medicine, vol. 341, no. 17, pp. 1284–1291, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. M. H. Houman and N. Bel Feki, “Pathophysiology of Behçet's disease,” La Revue de Medecine Interne, vol. 35, no. 2, pp. 90–96, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. International Study Group for Behçet's Disease (ISG), “Criteria for diagnosis of Behcet's disease,” The Lancet, vol. 335, no. 8697, pp. 1078–1080, 1990. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Al-Mujaini and U. K. Wali, “Frosted branch angiitis, neuroretinitis as initial ocular manifestation in Behçet disease,” Indian Journal of Ophthalmology, vol. 59, no. 3, pp. 240–241, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. R. O. Kaçmaz, J. H. Kempen, C. Newcomb et al., “Ocular inflammation in Behçet’s disease: incidence of ocular complications and loss of visual acuity,” American Journal of Ophthalmology, vol. 146, no. 6, pp. 828–836, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Tugal-Tutkun, S. Onal, R. Altan-Yaycioglu, H. Huseyin Altunbas, and M. Urgancioglu, “Uveitis in Behçet disease: an analysis of 880 patients,” American Journal of Ophthalmology, vol. 138, no. 3, pp. 373–380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. A. Okada, “Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature,” Ocular Immunology and Inflammation, vol. 13, no. 5, pp. 335–351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. R. J. Taylor, Z. Habot-Wilner, P. Pacheco, and S. Lightman, “Intravitreal methotrexate in uveitis,” Ophthalmology, vol. 119, no. 4, pp. 878–879, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Tugal-Tutkun, “Behçet's uveitis,” Middle East African Journal of Ophthalmology, vol. 16, pp. 219–224, 2009. View at Google Scholar
  10. M. Cutolo, A. Sulli, C. Pizzorni, B. Seriolo, and R. H. Straub, “Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 60, no. 8, pp. 729–735, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. World Medical Association Declaration of Helsinki, “Ethical principles for medical research involving human subjects,” Journal of the American Medical Association, vol. 310, no. 20, pp. 2191–2194, 2013. View at Google Scholar
  12. Z. Saleh and T. Arayssi, “Update on the therapy of Behçet's disease,” Therapeutic Advances in Chronic Disease, vol. 5, no. 3, pp. 112–134, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. J. Woo and E. H. Kang, “Use of Methotrexate for the treatment of Ocular Inflammation and Uveitis,” Pharmacovigilance, vol. 1, article 117, 2013. View at Google Scholar
  14. B. F. Hogewind, C. Zijlstra, B. J. Klevering, and C. B. Hoyng, “Intravitreal TAA for the treatment of refractory ME in idiopathic intermediate or posterior uveitis,” European Journal of Ophthalmology, vol. 18, no. 3, pp. 429–434, 2008. View at Google Scholar
  15. S. R. J. Taylor, A. Banker, A. Schlaen et al., “Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis,” Retina, vol. 33, no. 10, pp. 2149–2154, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. H. E. M. Khalil, H. A. Raafat, N. A. Azab, H. E. Haroun, and H. A. Elgendi, “The role of intraocular methotrexate in the management of uveitis and posterior segment involvement in Behçet's disease patients,” The Egyptian Rheumatologist, vol. 37, no. 3, pp. 113–118, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. A. B. Thach, P. U. Dugel, R. J. Flindall, J. O. Sipperley, and S. R. Sneed, “A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications,” Ophthalmology, vol. 104, no. 12, pp. 2003–2008, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. A. A. Okada, T. Wakabayashi, Y. Morimura et al., “Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis,” British Journal of Ophthalmology, vol. 87, no. 8, pp. 968–971, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. M. Gamal, Y. M. EL-Sayed, and K. A. El Einein, “Echography-verified retrobulbar triamcinolone injection in the treatment of uveitis,” Medical Journal Cairo University, vol. 77, no. 3, pp. 223–230, 2009. View at Google Scholar
  20. J. H. Bae and S. C. Lee, “Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease,” Retina, vol. 32, no. 7, pp. 1395–1402, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Roesel, M. Gutfleisch, C. Heinz, B. Heimes, B. Zurek-Imhoff, and A. Heiligenhaus, “Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis,” Eye, vol. 23, no. 4, pp. 910–914, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. S. R. J. Taylor, Z. Habot-Wilner, P. Pacheco, and S. L. Lightman, “Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema,” Ophthalmology, vol. 116, no. 4, pp. 797–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. L. Dafflon, V. T. Tran, Y. Guex-Crosier, and C. P. Herbort, “Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 237, no. 4, pp. 289–295, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Buiquoc, B. Bodaghi, R. Adam et al., “IOP elevation after subtenon injection of TAA during uveitis,” French Journal of Ophthalmology, vol. 25, no. 10, pp. 1048–1056, 2002. View at Google Scholar
  25. H.-K. Kuo, I.-C. Lai, P.-C. Fang, and M.-C. Teng, “Ocular complications after a sub-tenon injection of triamcinolone acetonide for uveitis,” Chang Gung Medical Journal, vol. 28, no. 2, pp. 85–89, 2005. View at Google Scholar · View at Scopus
  26. D. Ghate, W. Brooks, B. E. McCarey, and H. F. Edelhauser, “Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry,” Investigative Ophthalmology and Visual Science, vol. 48, no. 5, pp. 2230–2237, 2007. View at Publisher · View at Google Scholar · View at Scopus